I wonder if now that sbfm has obtained funding if they are still planning on selling adva27a after phase one clinical trials, should they make it that far. Is the grant money enough to carry them to/through phase 1??..?? I guess for the most part the costs are normal operating expenses, the synthesizing of adva27a for animal/clinical trials and a few other miscellaneous costs, anything else.?
Market Data 
Markets 
AI
